Curis Overview
- Status
-
Public
- Employees
-
24
- Stock Symbol
-
CRIS
- Investments
-
2
- Share Price
-
$0.43
- (As of Friday Closing)
Curis General Information
Description
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Contact Information
Website
www.curis.comCorporate Office
- 128 Spring Street
- Building C - Suite 500
- Lexington, MA 02421
- United States
Corporate Office
- 128 Spring Street
- Building C - Suite 500
- Lexington, MA 02421
- United States
Curis Timeline
Curis Stock Performance
As of 20-Nov-2026, Curis’s stock price is $0.43. Its current market cap is $4.06M with 9.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.43 | $0.47 | $0.33 - $28.40 | $4.06M | 9.5M | 4.27M | $7.83 |
Curis Financials Summary
As of 30-Sep-2026, Curis has a trailing 12-month revenue of $1.14M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (1,994) | 5,679 | 8,315 | 9,745 |
| Revenue | 1,138 | 9,443 | 10,908 | 10,023 |
| EBITDA | (19,515) | (5,544) | (44,339) | (48,077) |
| Net Income | (21,544) | (7,582) | (43,389) | (47,413) |
| Total Assets | 18,799 | 19,966 | 41,265 | 77,282 |
| Total Debt | 740 | 1,618 | 2,954 | 2,794 |
Curis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Curis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Curis Comparisons
Industry
Financing
Details
Curis Competitors (101)
One of Curis’s 101 competitors is ImmunityBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
Curis Patents
Curis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025208000-A1 | Methods of treating cancer in patients with altered protein expression | Pending | 29-Mar-2024 | ||
| WO-2025174879-A1 | Methods of reducing or eliminating measurable residual disease | Pending | 12-Feb-2024 | ||
| AU-2024368208-A1 | Methods of treating cancer associated with reduced interleukin 1 beta expression | Pending | 27-Oct-2023 | ||
| EP-4798194-A1 | Methods of treating cancer associated with reduced interleukin 1 beta expression | Pending | 27-Oct-2023 | ||
| WO-2025090844-A1 | Methods of treating cancer associated with reduced interleukin 1 beta expression | Inactive | 27-Oct-2023 | A61P35/00 |
Curis Signals
Curis Acquisitions (2)
Curis’s most recent deal was a Merger/Acquisition with Creative Biomolecules. The deal was made on 31-Jul-2000.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Creative Biomolecules | 31-Jul-2000 | Merger/Acquisition | Drug Discovery | ||
| Reprogenesis | 31-Jul-2000 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Curis ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.14 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Curis FAQs
-
Where is Curis headquartered?
Curis is headquartered in Lexington, MA.
-
What is the size of Curis?
Curis has 24 total employees.
-
What industry is Curis in?
Curis’s primary industry is Biotechnology.
-
Is Curis a private or public company?
Curis is a Public company.
-
What is Curis’s stock symbol?
The ticker symbol for Curis is CRIS.
-
What is the current stock price of Curis?
As of 20-Nov-2026 the stock price of Curis is $0.43.
-
What is the current market cap of Curis?
The current market capitalization of Curis is $4.06M.
-
What is Curis’s current revenue?
The trailing twelve month revenue for Curis is $1.14M.
-
Who are Curis’s competitors?
ImmunityBio, Aura Biosciences, Immunocore Holdings, Adaptimmune Therapeutics, and Sorrento Therapeutics are some of the 101 competitors of Curis.
-
What is Curis’s annual earnings per share (EPS)?
Curis’s EPS for 12 months was $7.83.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process